Navigation Links
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Date:11/24/2008

with peginterferon (without ribavirin), demonstrated enhanced antiviral activity, with up to 4 log10 and 5 log10 decreases in circulating HCV, respectively.

Full results of the boceprevir HCV SPRINT-1 study and early phase clinical results with SCH 900518 are being submitted for presentation at a future medical meeting.

About the Boceprevir HCV SPRINT-1 Study

In this Phase II study, known as HCV SPRINT-1 (HCV Serine Protease Inhibitor Therapy-1), boceprevir (800 mg TID) was evaluated in three treatment regimens: 4 weeks of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) therapy followed by the addition of boceprevir to the combination for 24 or 44 weeks (totaling 28 or 48 weeks of treatment), boceprevir in combination with PEGINTRON and REBETOL at the doses described above for 28 or 48 weeks, and, in Part II of the study, boceprevir in combination with PEGINTRON and low-dose REBETOL (400-1000 mg daily based on patient weight) for 48 weeks, compared to a control of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) alone for 48 weeks (an approved treatment regimen). The primary endpoint of the study is SVR after 24 weeks of follow up (SVR 24). SVR rates are not yet available for Part II of this study evaluating boceprevir with low-dose REBETOL (n=59) compared to contemporaneous control (n=16) as described above.

About Boceprevir Phase III Studies

Schering-Plough is conducting two large ongoing pivotal Phase III studies of boceprevir in patients chronically infected with HCV genotype 1. One study is in treatment-naive patients and the other in patients who failed prior treatment (relapsers and nonresponders). The two randomized, double-blind, placebo-controlled studies evaluate the efficacy of boceprevir in combination with PEGINTRON and REBETOL compared to standard of care
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
2. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
3. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
4. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
7. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
9. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... SAN DIEGO , Sept. 19, 2014 /PRNewswire/ ... industry leader in bioactive lipid-targeted therapeutics, announced today ... sell 3,605,042 registered shares of common stock and ... The combined purchase price for one registered share ... purchase one unregistered share of common stock will ...
(Date:9/19/2014)... LONDON , September 19, 2014 ... hat Pharma IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, ... abdeckt. Die interaktive PDF, verfügbar unter pharmaserialisation.com ... an dem sie jeweils in Kraft treten. ... der Serialisierung nicht länger um das "ob", sondern ...
(Date:9/19/2014)... Sept. 19, 2014  CytRx Corporation (Nasdaq: ... in oncology, today announced that David J. Haen ... 2014 NewsMakers in the Biotech Industry Conference on Friday, September ... conference will take place at the Millennium Broadway Hotel ... A live and archived webcast of the presentation ...
Breaking Medicine Technology:Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3
... U.S. Food and Drug Administration is warning the public ... law enforcement personnel as part of a continued international ... The criminals call the victims -- who ... or via "telepharmacies" -- and identify themselves as FDA ...
... EDDA Technology, a leading provider of advanced computer ... successful commercial installation of its IQQA®-Liver Enterprise product ... one of the top performing living donor liver ... use EDDA Technology,s IQQA®-Liver Enterprise in conjunction with ...
Cached Medicine Technology:FDA Warns Public of Continued Extortion Scam By FDA Impersonators 2FDA Warns Public of Continued Extortion Scam By FDA Impersonators 3EDDA Technology Successfully Installs IQQA®-Liver at Mayo Clinic in Arizona 2
(Date:9/19/2014)... Forest Hills, NY (PRWEB) September 20, 2014 ... Periodontist Prabha Krishnan DMD in Queens, NY now reminds area ... “With more than 80% of our population affected by gum ... problem any longer.” , For over 20 years Dr. Krishnan ... her Forest Hills office location. “Most patients that come in ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Recently, ... and announced that JustHost, IX Web Hosting and ... , “As is known to most people, ... partitioning a physical server computer into many servers, ... of running on someone’s own dedicated computer,” the ...
(Date:9/19/2014)... proteins and large protein complexes are notoriously difficult to ... often very difficult, if not impossible, to crystallize, but ... flexible. The result is that when a structure can ... and reveals a mosaic-like spread of protein domains that ... & Brunger. (2014), Acta Cryst . D70, 2241-2255; ...
(Date:9/19/2014)... September 19, 2014 Top10BestSEOHosting.com today ... announces that HostMonster, Arvixe and Bluehost are the ... buy high quality WordPress hosting (including VPS and ... websites for more detailed information. , HostMonster ( ... high-powered service at a fraction of the cost. ...
(Date:9/19/2014)... Texas (PRWEB) September 19, 2014 Singulair, ... the physiologic actions of leukotriene D4 (LTD4). LTD4 belongs ... from a variety of cells, including mast cells and ... receptors. Several studies have determined that there are higher ... asthmatics compared with non-asthmatic individuals. The production of CysLTs ...
Breaking Medicine News(10 mins):Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:Top10BestSEOHosting.com: JustHost is One of the Best VPS Suppliers in 2014 2Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3Health News:Top10BestSEOHosting.com: They Are Best Windows Web Hosting Suppliers Of 2014 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 4
... the University of Florida have initiated a project to ... secrets of regeneration from creatures with remarkable powers of ... ,Fueled by about $6 million in private donations, university ... connect scientists who work with adult human stem cells ...
... seventeen patients have been dead due to the infection of ... have died after contracting Clostridium Difficile, commonly known as C ... also reported that few of the patients were infected with ... strain. Major bowel surgery had to be performed on five ...
... the FDA launched a special Web page. This web page ... isotretinoin, sold by Roche// under the brand name Accutane, on ... acne that is not controlled by other treatment forms. FDA ... and severe mental health problems. ,The FDA warning ...
... the cancer drugs to be given freely to patients. They ... 1// and appealed to Northern Ireland's new assembly to follow ... diagnosed with cancer every year. Heather Monteverde from the charity ... as it causes a huge financial burden on them. ...
... at Birmingham's Magnetic Source Imaging Laboratory are studying the ... to learn more about the intricacies of brain pathology. ... the geography of the brain or detect blood flow, ... throw off as they communicate. "You can look at ...
... was shortened as Calgaria. But this has failed to soothe ... insult those afflicted by mental sickness. ,“I realize ... those of us living with mental illness who have to ... who suffers from depression and sits on the board for ...
Cached Medicine News:Health News:UF Launches Project to Bridge the Regeneration Gap 2Health News:UF Launches Project to Bridge the Regeneration Gap 3Health News:Web Page to Warn Against Online Purchase of Isotretinoin 2Health News:MEG Scanners Are Mega Powerful 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... (RAM) is the first visual examination device that ... in eyes with glaucoma, cataract, and macular disease. ... test each eye easily in under 60 seconds. ... Columbia University in New York City, the RAM ...
Medicine Products: